Rebecca Chambers Net Worth

The estimated Net Worth of Rebecca Chambers is at least $957 Tisíc dollars as of 21 June 2024. Ms Chambers owns over 260 units of Veracyte Inc stock worth over $293,619 and over the last 4 years she sold VCYT stock worth over $55,713. In addition, she makes $607,650 as Exec. VP & CFO at Veracyte Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms Chambers VCYT stock SEC Form 4 insiders trading

Ms has made over 6 trades of the Veracyte Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently she sold 260 units of VCYT stock worth $11,957 on 21 June 2024.

The largest trade she's ever made was exercising 16,727 units of Veracyte Inc stock on 24 June 2021 worth over $104,544. On average, Ms trades about 2,620 units every 46 days since 2021. As of 21 June 2024 she still owns at least 9,684 units of Veracyte Inc stock.

You can see the complete history of Ms Chambers stock trades at the bottom of the page.

Ms. Rebecca Chambers biography

Rebecca Chambers is the Exec. VP & CFO at Veracyte Inc.

What is the salary of Ms Chambers?

As the Exec. VP & CFO of Veracyte Inc, the total compensation of Ms Chambers at Veracyte Inc is $607,650. There are 3 executives at Veracyte Inc getting paid more, with Bonnie H. Anderson having the highest compensation of $1,252,000.

How old is Ms Chambers?

Ms Chambers is 43, she's been the Exec. VP & CFO of Veracyte Inc since . There are 7 older and 2 younger executives at Veracyte Inc. The oldest executive at Veracyte Inc is Dr. Tina S. Nova Ph.D., 67, who is the Pres of CLIA U.S. Bus..

Insiders trading at Veracyte Inc

Over the last 11 years, insiders at Veracyte Inc have traded over $201,983,044 worth of Veracyte Inc stock and bought 75,122 units worth $1,149,322 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Nicole Vitullo a Jesse I Treu. On average, Veracyte Inc executives and independent directors trade stock every 20 days with the average trade being worth of $804,905. The most recent stock trade was executed by John Leite on 4 September 2024, trading 5,479 units of VCYT stock currently worth $163,165.

What does Veracyte Inc do?

veracyte is a pioneering genomic diagnostics company. our tests are dramatically improving clinical outcomes for patients by resolving inconclusive results from traditional diagnostic methods. we ask the right questions to resolve ambiguity and bring assurance to light, rendering tens of thousands of costly and unnecessary surgeries truly unnecessary. we are giving patients a clearer path forward. through scientific rigor we employ the best tools, best science and best minds to create tests that enable a more accurate diagnosis without the need for risky, costly and often unnecessary surgery. veracyte consistently brings to bear evidence that is unprecedented in genomic tests, thereby changing today's clinical practice standards. we are making a difference in the lives of physicians and patients. we are doing something real. .

Complete history of Ms Chambers stock trades at Veracyte Inc, Inari Medical a Outset Medical

Veracyte Inc executives and stock owners

Veracyte Inc executives and other stock owners filed with the SEC include:

• Bonnie H. Anderson,
  Co-Founder & Exec. Chairwoman
• Dr. Giulia C. Kennedy Ph.D.,
  Global Chief Scientific Officer & Chief Medical Officer
• John Walter Hanna Jr.,
  Chief Commercial Officer and GM of Endocrinology, Breast Cancer & Lymphoma
• Rebecca Chambers,
  Exec. VP & CFO
• Dr. Tina S. Nova Ph.D.,
  Pres of CLIA U.S. Bus.
• Annie McGuire,
  Sr. VP & Gen. Counsel
• Jonathan Wygant,
  VP & Chief Accounting Officer
• Robert Brainin,
  Exec. VP & Chief Bus. Officer
• Dr. Alfred Bowie Jr., Ph.D.,
  VP of Corp. & Bus. Devel.
• Tracy Morris,
  VP of Corp. Communications & Investor Relations
• William W. Zondler,
  Sr. VP & Chief Information Officer
• Beverly Jane Alley CPA,
  VP, Corp. Controller & Principal Accounting Officer
• Marc A. Stapley,
  CEO & Director
• Marc Stapley,
  Chief Executive Officer
• Rebecca Chambers,
  Chief Financial Officer
• Karin Eastham,
  Director
• Brian G Atwood,
  Director
• Keith Kennedy,
  COO / CFO
• Christopher M Hall,
  Chief Commercial Officer
• Perkins Caufield & Byers Xi...,
  
• John L Bishop,
  Director
• Evan/ Fa Jones,
  Director
• Fred E Cohen,
  Director
• Shelly D Guyer,
  Chief Financial Officer
• Robert S Epstein,
  Director
• Kevin K Gordon,
  Director
• Muna Bhanji,
  Director
• Julie Brooks,
  EVP,General Counsel,Secretary
• Jesse I Treu,
  Director
• Giulia C Kennedy,
  Chief Scientific & Med Officer
• Bonnie H Anderson,
  Director
• Ventures Iii, Llc Versant V...,
  
• Viii Associates, L.P. Dp,
  10% owner
• Kathleen K Schoemaker,
  10% owner
• Group Holdings (Sbs) Adviso...,
  
• Brook H Byers,
  Director
• Brian K Halak,
  10% owner
• Duncan Thomas Powell,
  Principal Accounting Officer
• Partners Viii, L.P.Blair Ja...,
  
• Samuel D Colella,
  Director
• Brian H Dovey,
  10% owner
• Nicole Vitullo,
  10% owner
• Partners Viii, L.P. Domain,
  10% owner
• James C Blair,
  10% owner
• John Walter Jr Hanna,
  Chief Commercial Officer
• Mark Ho,
  
• Iii James H Erlinger,
  
• Jens Holstein,
  Director
• John Leite,
  Chief Commercial Officer-CLIA
• Beverly Jane Alley,
  VP, Corporate Controller
• David Brent Shafer,
  Director
• Thomas F. Miller,
  Director
• Tina Susan Nova,
  President, CLIA U.S.
• Annie Mc Guire,
  SVP, General Counsel
• Eliav Barr,
  Director
• Jonathan Wygant,
  VP, Chief Accounting Officer
• Phillip G. Febbo,
  Chief Scientific & Med Officer